Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl Phosphate
2. Fmod Phosphate
3. Sodium 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl Phosphate
1. Cvm-1118
2. Foslinanib [inn]
3. Foslinanib [usan]
4. Trx 818
5. Trx-818
6. 2x2dnm7ngx
7. Trx-818 Free Acid
8. Cvm-1118 Free Acid
9. 1256037-60-1
10. 4(1h)-quinolinone, 2-(3-fluorophenyl)-6-methoxy-5-(phosphonooxy)-
11. 2-(3-fluorophenyl)-4-hydroxy-6-methoxyquinolin-5-yl Dihydrogen Phosphate
12. 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl Dihydrogen Phosphate
13. 2054938-73-5
14. Foslinanib (usan/inn)
15. Foslinanib [usan:inn]
16. Unii-2x2dnm7ngx
17. Foslinanib [who-dd]
18. Schembl339272
19. Chembl1615993
20. Gtpl11621
21. Who 10721
22. D11639
23. 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl Phosphate
24. [2-(3-fluorophenyl)-6-methoxy-4-oxo-1h-quinolin-5-yl] Dihydrogen Phosphate
| Molecular Weight | 365.25 g/mol |
|---|---|
| Molecular Formula | C16H13FNO6P |
| XLogP3 | 1.6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 365.04645229 g/mol |
| Monoisotopic Mass | 365.04645229 g/mol |
| Topological Polar Surface Area | 105 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 593 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Foslinanib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Foslinanib, including repackagers and relabelers. The FDA regulates Foslinanib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Foslinanib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Foslinanib supplier is an individual or a company that provides Foslinanib active pharmaceutical ingredient (API) or Foslinanib finished formulations upon request. The Foslinanib suppliers may include Foslinanib API manufacturers, exporters, distributors and traders.
Foslinanib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Foslinanib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Foslinanib GMP manufacturer or Foslinanib GMP API supplier for your needs.
A Foslinanib CoA (Certificate of Analysis) is a formal document that attests to Foslinanib's compliance with Foslinanib specifications and serves as a tool for batch-level quality control.
Foslinanib CoA mostly includes findings from lab analyses of a specific batch. For each Foslinanib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Foslinanib may be tested according to a variety of international standards, such as European Pharmacopoeia (Foslinanib EP), Foslinanib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Foslinanib USP).
LOOKING FOR A SUPPLIER?
